Carnitine palmitoyltransferase
From Proteopedia
| Line 16: | Line 16: | ||
[[2rcu]] – rCPT II + substrate analog<br /> | [[2rcu]] – rCPT II + substrate analog<br /> | ||
[[4ep9]], [[4eph]], [[4eyw]] - rCPT II + inhibitor<br /> | [[4ep9]], [[4eph]], [[4eyw]] - rCPT II + inhibitor<br /> | ||
| - | [[2le3]] – | + | [[2le3]] – hCPT I regulatory domain – human - NMR<br /> |
| + | [[2m76]] - hCPT I regulatory domain – NMR<br /> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 11:49, 16 February 2014
Carnitine palmitoyltransferase (CPT I and CPT II) are involved in the transport of long-chain fatty acids into the mitochondria where they are oxidized. Fatty acids form a conjugate with CoA before being oxidized in the mitochondria. However, the CoA-long-chain fatty acid conjugates can not diffuse into the mitochondria. CPT I is a membrane protein which substitutes the CoA in the long-chain fatty acids by carnitine. After entering the mitochondria, CPT II exchanges the carnitine by CoA, enabling the oxidation of the long-chain fatty acids. CPT I is important in fatty acid disorders like diabetes.
3D structures of carnitine palmitoyltransferase
Updated on 16-February-2014
2h4t, 2fyo, 2deb – rCPT II – rat
2fw3 - rCPT II + antidiabetic drug
2rcu – rCPT II + substrate analog
4ep9, 4eph, 4eyw - rCPT II + inhibitor
2le3 – hCPT I regulatory domain – human - NMR
2m76 - hCPT I regulatory domain – NMR
